Q2 EPS Forecast for ENDRA Life Sciences Lifted by Analyst

ENDRA Life Sciences Inc. (NASDAQ:NDRA) – Investment analysts at Ascendiant Capital Markets raised their Q2 2026 earnings estimates for shares of ENDRA Life Sciences in a research report issued on Sunday, May 31st. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will post earnings per share of ($0.84) for the quarter, up from their previous estimate of ($1.14). Ascendiant Capital Markets has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for ENDRA Life Sciences’ current full-year earnings is ($4.65) per share. Ascendiant Capital Markets also issued estimates for ENDRA Life Sciences’ Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.84) EPS, FY2026 earnings at ($4.11) EPS, Q1 2027 earnings at ($0.80) EPS, Q2 2027 earnings at ($0.76) EPS, Q3 2027 earnings at ($0.74) EPS, Q4 2027 earnings at ($0.74) EPS and FY2027 earnings at ($3.04) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of ENDRA Life Sciences in a report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, ENDRA Life Sciences currently has an average rating of “Hold” and a consensus target price of $25.00.

ENDRA Life Sciences Stock Down 6.2%

ENDRA Life Sciences stock opened at $4.73 on Thursday. The stock has a market cap of $6.01 million, a P/E ratio of -0.58 and a beta of -0.04. ENDRA Life Sciences has a twelve month low of $2.96 and a twelve month high of $11.96. The company’s 50-day moving average price is $5.09 and its two-hundred day moving average price is $4.73.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings results on Friday, May 15th. The company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.23) by $0.14.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC purchased a new stake in ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences accounts for about 0.9% of Altium Capital Management LLC’s portfolio, making the stock its 17th biggest position. Altium Capital Management LLC owned about 6.92% of ENDRA Life Sciences at the end of the most recent reporting period. Institutional investors and hedge funds own 1.19% of the company’s stock.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.